Lactoferrin (17-41)
Based on 1 Customer Validation
Lactoferrin 17-41 (Lactoferricin B), a peptide corresponding to residues 17-41 of bovine lactoferrin, has antimicrobial activity against a wide range of microorganisms, including Gram-positive and Gramnegative bacteria, viruses, protozoa, and fungi. Lactoferrin 17-41 has antitumor activities.
For research use only. We do not sell to patients.
- Purity : 98.98%
- CAS No.: 146897-68-9
- Formula: C141H224N46O29S3
- Molecular Weight:3123.77
-
Storage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Biological Activity
Description
In Vitro
Lactoferrin 17-41 (Lactoferricin B) has an MIC of 30 μg/ml against E. coli ATCC 25922[1].
Lactoferrin 17-41 significantly stimulates apoptosis of HT-29 cells and displays cytotoxic activity on HT-29 cells[2].
Lactoferrin 17-41 variously regulats transcription of genes involved in the p53 signaling pathway, such as PMAIP-1, TP5313, and SFN[2].
Lactoferrin 17-41 can bind LPS from Gram-negative bacteria and that it can inhibit LPS induced cytokine response in human monocytic cells[1][3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HT-29 cells
-
Concentration:50, 100, 200, 400, 800 or 1000 µg/mL
-
Incubation Time:4, 12, 24 or 48 hours
-
Result:More effective at inducing apoptosis at 400 µg/mL. Higher toxicity is shown at 800 µg/mL.
Chemical Information
-
CAS No. 146897-68-9
-
Appearance Solid
-
Molecular Weight 3123.77
-
Formula C141H224N46O29S3
-
Color White to off-white
-
Synonyms
Lactoferricin B; Lfcin B
-
Sequence
Phe-Lys-Cys-Arg-Arg-Trp-Gln-Trp-Arg-Met-Lys-Lys-Leu-Gly-Ala-Pro-Ser-Ile-Thr-Cys-Val-Arg-Arg-Ala-Phe (Disulfide bridge: Cys3-Cys20)
-
Sequence Shortening
FKCRRWQWRMKKLGAPSITCVRRAF (Disulfide bridge: Cys3-Cys20)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Gram Staining of Tissue Sections
Gram staining of tissue sections is a histochemical technique used to differentiate Gram-positive and Gram-negative bacteria within histological specimens based on differences in bacterial cell wall structure and dye retention, adapted from classical bacteriological Gram staining into tissue-compatible “histological Gram stain” variants. In tissue applications, modifications of the Brown-Hopps and Brown-Brenn methods are commonly used to improve differentiation of microorganisms embedded within host connective tissue and to reduce overstaining or loss of Gram-negative signal, which are known limitations of earlier approaches. The principle relies on crystal violet-iodine complex retention in Gram-positive organisms and subsequent decolorization and counterstaining steps that allow contrast visualization of Gram-negative organisms against tissue background.
Purity & Documentation
-
Data Sheet (263 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
References
[1]. Samuelsen Ø, et al. Anti-complement effects of lactoferrin-derived peptides. FEMS Immunol Med Microbiol. 2004 Jun 1;41(2):141-8. [Content Brief]
[2]. Jiang R, et al. Bovine lactoferrin and lactoferricin exert antitumor activities on human colorectal cancer cells(HT-29) by activating various signaling pathways. Biochem Cell Biol. 2017 Feb;95(1):99-109. [Content Brief]
[3]. Latorre D, et al. Reciprocal interactions between lactoferrin and bacterial endotoxins and their role in the regulation of the immune response. Toxins (Basel). 2010;2(1):54‐68. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)